Newsletter | June 2, 2023

06.02.23 -- From Biggest Pharma To Rare Disease Start-Up

New Podcast Episode
Featured Articles
More Transparency, To A Point

New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?

Attributes Gaining Importance When Selecting Among Preferred Providers For Phase 1 Services

The service provider selection process is a complicated one. Many factors come into play during this process. One critical factor is undoubtedly the presence of preferred provider agreements. Companies can spend a great deal of time negotiating these agreements, and their presence, or lack thereof, can make or break which CROs are shortlisted or awarded a Phase 1 study.

From Biggest Pharma To Rare Disease Startup

Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech. 

Web-Exclusive Content
FDA Releases Draft Guidance On Decentralized Clinical Trials

The FDA has released a new draft guidance, Decentralized Clinical Trials for Drugs, Biological Products, and Devices. Check out the key takeaways related to remote trial visits, digital health technologies, and more. The public comment period ends August 1, 2023.

Industry Insights
Pursuing Venture Philanthropy With Opus Genetics: The Business Of Biotech

Opus Genetics' Dr. Ben Yerxa explores overcoming the obstacles inherent to bringing rare disease treatments to market in a recent episode of The Business of Biotech.

5 Tips To Better Engage With Digital Opinion Leaders

Engaging with digital opinion leaders is essential to growing brand recognition and moving products forward. Follow these five tips to better connect with experts online.

Analysis Paralysis: Navigating Early-Phase Analytical Validation

Qualification’s reduced set of testing requirements aim to demonstrate a method is suitable for its intended purpose, but it typically is not as robust as method validation.

Digital Edition
June 2023 Digital Edition

Inside you will find more on:

  • Companies To Watch
  • Podcast Series Review
  • Clinical Trials Topics
  • Manufacturing Topics

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.